Composition, food and drink, and pharmaceutical containing lactic acid bacterium

Abstract

The present invention provides a composition for use in applications such as activating plasmacytoid dendritic cells (pDCs), the composition containing Lactobacillus sakei, MG-LAB279 strain (accession number: NITE BP-03645), and / or a bacterial cell component thereof as an active ingredient.

Description

Composition, food and drink product, and pharmaceutical product containing lactic acid bacteria

[0001] The present invention relates to a composition, a food and drink product, and a pharmaceutical product containing Lactobacillus sakei MG-LAB279 strain (accession number: NITE BP-03645) and / or its cell components.

[0002] Lactic acid bacteria are a general term for microorganisms that produce lactic acid from sugars. Lactic acid bacteria are known to exist in the human intestine and have the function of suppressing the growth of harmful bacteria and regulating the intestinal environment.

[0003] Patent Document 1 discloses a new lactic acid bacterium, Lactobacillus sakei MG-LAB279 strain, and discloses that the strain enhances the production of IL-12p70 and IFN-λ.

[0004] International Publication No. 2023 / 218898

[0005] An object of the present invention is to provide a lactic acid bacteria-containing composition that can be used in various applications.

[0006] The present inventors have found that a composition containing Lactobacillus sakei MG-LAB279 strain and / or its cell components can be used in various applications.

[0007] The present invention includes the following embodiments: [1] A composition for activating plasmacytoid dendritic cells (pDCs), comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its cellular components as an active ingredient. [2] The composition according to [1], wherein the activation improves the expression of at least one gene selected from the group consisting of HLA-DR, CD197 (CCR7), CD40, CD83, and CD86. [3] A composition for improving the expression of at least one gene selected from the group consisting of HLA-DR, CD197 (CCR7), CD40, CD83, and CD86 in plasmacytoid dendritic cells (pDCs), comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient. [4] A composition for improving the intestinal environment, comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient. [5] A composition for improving abdominal discomfort, comprising Lactobacillus sakei MG-LAB279 strain (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient. [6] A composition for improving abdominal pain, comprising Lactobacillus sakei MG-LAB279 strain (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient. [7] A composition for improving appetite, comprising Lactobacillus sakei MG-LAB279 strain (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient. [8] A composition for improving mood, comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its cellular components as an active ingredient.[9] A composition for reducing fatigue, containing Lactobacillus sakei MG-LAB279 strain (accession number: NITE BP-03645) and / or its cell components as an active ingredient.

[10] A composition for reducing drowsiness, containing Lactobacillus sakei MG-LAB279 strain (accession number: NITE BP-03645) and / or its cell components as an active ingredient.

[11] A composition for suppressing skin dryness, containing Lactobacillus sakei MG-LAB279 strain (accession number: NITE BP-03645) and / or its cell components as an active ingredient.

[12] A composition for improving liver function, comprising Lactobacillus sakei MG-LAB279 strain (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient.

[13] A composition for reducing body fat, comprising Lactobacillus sakei MG-LAB279 strain (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient.

[14] Food and beverages comprising the composition described in any of [1] to

[13] .

[15] Pharmaceuticals comprising the composition described in any of [1] to

[13] .

[0008] The present invention can provide a lactic acid bacteria-containing composition that can be used for various applications.

[0009] The results of blood pDC activity (Figure 1A: HLA-DR, Figure 1B: CD197 / CCR7, Figure 1C: CD40, Figure 1D: CD83, Figure 1E: CD86) are shown. The results of subjective evaluations regarding the abdomen (Figure 2A: abdominal discomfort, Figure 2B: abdominal pain, Figure 2C: loss of appetite) are shown. The results of subjective evaluations regarding psychology are shown. The results of subjective evaluations regarding fatigue are shown. The results of subjective evaluations regarding sleep are shown. Measurement results regarding skin moisture content of male subjects are shown. The effects of alcohol intake (Figure 7A: body weight, Figure 7B: food intake, Figure 7C: ethanol aqueous solution intake, Figure 7D: appearance of the mouse) are shown. The results of serum biochemical tests (Figure 8A: AST / ALT, Figure 8B: LDH, Figure 8C: LDL-C, Figure 8D: HDL-C) are shown.

[0010] The embodiments of the present invention will be described in detail below, but the present invention is not limited to these, and various modifications are possible without departing from the spirit of the invention.

[0011] One embodiment of the present invention relates to a composition containing Lactobacillus sakei MG-LAB279 strain (accession number: NITE BP-03645) and / or its cellular components as an active ingredient.

[0012] Lactobacillus sakei MG-LAB279 strain (hereinafter also simply referred to as "bacterial cells") is a lactic acid bacterium with accession number NITE BP-03645, deposited with the Patent Microorganism Depository Center of the National Institute of Technology and Evaluation on May 2, 2022.

[0013] The bacterial cells contained in the composition according to this embodiment may be live or dead. While not particularly limited, it is preferable that the bacterial cells be dead.

[0014] The composition according to this embodiment may be a food or beverage (including Foods for Specified Health Uses, Foods with Nutrient Function Claims, Foods with Function Claims, and Animal Feed) or a pharmaceutical product (including quasi-drugs).

[0015] The composition according to this embodiment can be used to activate plasmacytoid dendritic cells (pDCs).

[0016] The composition according to this embodiment can be used to improve the expression of at least one gene selected from the group consisting of HLA-DR, CD197 (CCR7), CD40, CD83, and CD86, which are activation markers for pDCs. In this specification, improvement of activation marker expression includes increasing the expression of the activation marker and suppressing the decrease in the expression of the activation marker. Preferably, the composition according to this embodiment can increase the expression of CD40. Preferably, the composition according to this embodiment can increase the expression of CD86. Preferably, the composition according to this embodiment can suppress the decrease in the expression of HLA-DR. Preferably, the composition according to this embodiment can suppress the decrease in the expression of CD197 (CCR7). Preferably, the composition according to this embodiment can suppress the decrease in the expression of CD83.

[0017] The composition according to this embodiment can be used to improve the intestinal environment (for example, the intestinal microbiota).

[0018] The composition according to this embodiment can be used to improve abdominal discomfort.

[0019] The composition according to this embodiment can be used to alleviate abdominal pain.

[0020] The composition according to this embodiment can be used to improve appetite.

[0021] The composition according to this embodiment can be used to improve mood.

[0022] The composition according to this embodiment can be used to reduce fatigue.

[0023] The composition according to this embodiment can be used to reduce drowsiness (preferably drowsiness upon waking).

[0024] The composition according to this embodiment can be used to suppress skin dryness (in other words, to maintain the skin's moisture content).

[0025] The composition according to this embodiment can be used to improve liver function. In this specification, improvement of liver function includes enhancing liver function, suppressing the decline of liver function, and preventing or treating liver dysfunction.

[0026] The composition according to this embodiment can be used to reduce alcohol consumption. In other words, the composition according to this embodiment can be used to prevent or treat alcohol poisoning.

[0027] The composition according to this embodiment can be used to suppress the increase in blood concentration of at least one selected from the group consisting of aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid (UA), lactate dehydrogenase (LDH), LDL cholesterol, and HDL cholesterol (preferably at least one selected from the group consisting of AST, LDH, and LDL cholesterol).

[0028] The composition according to this embodiment can be used to reduce body fat.

[0029] Various culture media can be used to culture Lactobacillus sakei MG-LAB279 strain, including milk media, media containing milk components, and semi-synthetic media that do not contain milk components. An example of such a medium is reduced skim milk medium, which is obtained by reducing skim milk and heat-sterilizing it.

[0030] The culture method for Lactobacillus sakei MG-LAB279 strain is static culture or neutralized culture with a controlled pH, but there are no particular restrictions on the culture method as long as the conditions are suitable for the growth of the bacteria. The bacterial cells can be cultured according to the standard method for culturing lactic acid bacteria, and the resulting culture can be used directly after being isolated by methods such as centrifugation.

[0031] Dead bacterial cells can usually be obtained by heating them. The heating conditions are not particularly limited as long as they kill the bacteria, but generally, heating at 90°C for about 30 minutes is sufficient to obtain good results.

[0032] The Lactobacillus sakei MG-LAB279 strain contained in the composition according to this embodiment is not limited to purely isolated bacterial cells, but may also be its culture, suspension, or other bacterial cell-containing material. Furthermore, it may also be cytoplasmic components such as nucleic acids or cell wall fractions obtained by treating the bacterial cells with enzymes or physical means. These may be used individually or in combination. Therefore, the dead Lactobacillus sakei MG-LAB279 strain may be a culture or the bacterial cells contained therein. In this case, the food, beverage, or pharmaceutical product containing the composition according to this embodiment may also contain the culture or the bacterial cells contained therein.

[0033] In the composition according to this embodiment, the bacterial cells may be mixed with dextrin to make them easier to handle. In this case, the composition according to this embodiment may contain 0.1 to 99% by mass of Lactobacillus sakei MG-LAB279 strain and 1 to 99.9% by mass of dextrin.

[0034] Lactobacillus sakei MG-LAB279 strain and / or its cellular components may be incorporated into any food or beverage, or added to raw materials during the manufacturing process of food or beverages. Examples of food and beverages include, for example, milk beverages, fermented milk, fruit juices, soft drinks, jellies, candies, chocolates, dairy products, egg products such as mayonnaise, and confectionery and bread such as butter cakes.

[0035] Lactobacillus sakey MG-LAB279 strain and / or its cellular components may be incorporated into any livestock feed, or added to the raw materials during the feed manufacturing process.

[0036] The method for formulating the composition according to this embodiment is not particularly limited other than using Lactobacillus sakei MG-LAB279 strain and / or its cellular components as the active ingredient, and can be formulated according to standard methods by appropriately mixing in excipients, stabilizers, flavoring agents, etc. that are permitted for formulation.

[0037] The composition according to this embodiment can also be formulated by mixing excipients, binders, disintegrants, lubricants, flavoring and odor-correcting agents, suspending agents, coating agents, and other arbitrary agents, as long as they do not interfere with the action of the bacterial cells or culture.

[0038] The composition according to this embodiment can be used for a wide range of applications such as pharmaceuticals, cosmetics, food and beverages, etc. These compositions can be tablets, pills, capsules, granules, powders, powders, syrups, etc., and it is desirable to administer them orally.

[0039] In order to exert various functions of the composition according to this embodiment, in the case of adults, the dosage of the heat-killed cells of Lactobacillus sakei MG-LAB279 strain is preferably 1 mg to 10 g / day, more preferably 10 mg to 1 g / day.

[0040] Hereinafter, the present invention will be described in more detail using examples and comparative examples, but the technical scope of the present invention is not limited thereto.

[0041] [Example 1] Preparation of heat-killed cells of MG-LAB279 strain Lactobacillus sakei MG-LAB279 strain was inoculated into MRS medium and statically cultured at 30 °C for 24 hours. The obtained culture solution was centrifugally concentrated, washed several times with distilled water, and a 10% lactic acid bacteria solution was prepared. Next, the lactic acid bacteria solution was sterilized by heating at 80 °C for 90 minutes. Then, it was spray-dried to obtain a powder of Lactobacillus sakei MG-LAB279 strain, which is a heat-killed cell.

[0042] [Example 2] Preparation of lactic acid bacteria-containing composition The heat-killed cell powder obtained in Example 1 was mixed with dextrin as an excipient and filled into capsules to obtain a lactic acid bacteria-containing composition (30 mg of heat-killed cell powder, 270 mg of dextrin).

[0043] [Comparative Example 1] Preparation of placebo Instead of Lactobacillus sakei MG-LAB279 strain, digestible dextrin that does not affect the immune activation effect was prepared, and the same amount as the composition of Example 2 was filled into capsules to obtain a placebo. Note that the lactic acid bacteria-containing composition of Example 2 and the placebo of Comparative Example 1 had the same taste and appearance.

[0044] [Test Example 1] Oral ingestion test (Subjects) Those who feel prone to catching colds and have a BMI of 17.5 kg / m ３Above 30.0 kg / m ３ Forty healthy Japanese adults aged 40 to 50 years, less than 30.0 kg / m, were recruited as subjects. The test content was fully explained to the subjects, and informed consent was obtained.

[0045] (Test method) Forty subjects were randomly divided into two groups: 20 subjects in the MG-LAB279 strain group (10 males, 10 females, average age 50.1 years) and 20 subjects in the placebo group (9 males, 11 females, average age 47.3 years). After grouping, a randomized double-blind placebo-controlled parallel-group comparison test was conducted between the two groups. The lactic acid bacteria-containing composition of Example 2 was administered to the MG-LAB279 strain group, and the placebo of Comparative Example 1 was administered to the placebo group, both at a dose of 1 capsule per day for 90 consecutive days.

[0046] (Test schedule) The effect of the lactic acid bacteria-containing composition was verified based on blood tests and subjective evaluations. Blood samples were collected twice, on day 0 (test start day) and day 90 (test end day) of ingestion. The subjects filled out a daily physical condition questionnaire during the ingestion period. Skin moisture measurements were taken three times, on day 0 (test start day), day 42 of ingestion, and day 90 (test end day) of ingestion.

[0047] (Evaluation items) The pDC activity in the blood (pDC surface markers: expression levels of HLA-DR, CD197 / CCR7, CD40, CD83, CD86 in CD123+ / BDCA4+ cells) was measured, and a subjective evaluation of physical condition was conducted using a questionnaire.

[0048] (Experimental method) In the analysis of blood biomarkers, human peripheral blood mononuclear cells (PBMCs) were isolated from the blood samples collected at the 0-week and 4-week examinations and used for the tests.

[0049] 1×10 ６Cell PBMCs were stained according to standard procedures using anti-CD123-FITC, anti-BDCA4-APC, anti-CD86-PE, anti-HLA-DR-PerCP, anti-CD83-BV421, anti-CD40-BV750, and anti-CD197-PE-CF594. The fluorescence intensity of HLA-DR, CD86, CD83, CD40, and CD197 in cell populations detected by CD123+ and BDCA4+ was measured using FACS Symphony A3 (BD ​​Corporation), and this was used as an indicator of pDC activity.

[0050] For each item in the questionnaire, evaluations were conducted daily as follows: For abdominal discomfort, poor appetite, and feelings of depression, irritability, or anxiety, responses were limited to either "yes" or "no." For morning sleepiness, responses were obtained according to the OSA sleep questionnaire, and for fatigue, responses were obtained according to the fatigue VAS test.

[0051] Skin moisture content was measured using a Corneometer CM825 on days 0, 42, and 90 of the study, specifically the stratum corneum moisture content of the skin on the inner right forearm. Three measurements were taken each time, and the average value was used as the measurement result.

[0052] (Results) The results of blood pDC activity are shown in Figure 1. Figure 1 (Figures 1A to 1E) shows the percentage change in the activity of MHC class II, HLA-DR, CD197 / CCR7, CD40, CD83, and CD86 in pDCs from day 0 to day 90. The percentage change was calculated using the following formula: Percentage change (%) = [(Value on day 90 - Value on day 0) × 100] / Value on day 0

[0053] Regarding the activity of CD40 and CD86, the MG-LAB279 strain group showed improved activity compared to the placebo group. Regarding the activity of HLA-DR, CD197 / CCR7, and CD86, the decrease in activity was suppressed in the MG-LAB279 strain group compared to the placebo group. These results indicate that the MG-LAB279 strain has a pDC activating effect.

[0054] The results of subjective evaluations regarding the abdomen are shown in Figure 2. Figure 2 (Figures 2A to 2C) shows the cumulative number of days with "abdominal discomfort," "abdominal pain," and "loss of appetite" from day 0 to day 90 of the study. For all items, the number of days was significantly lower in the MG-LAB279 strain group compared to the placebo group. In the comparison between the two groups, a significance level of less than 5% was considered statistically significant. These results indicate that the MG-LAB279 strain has the effect of improving abdominal condition.

[0055] Figure 3 shows the results of subjective evaluations regarding psychological state. Figure 3 shows the cumulative number of days with "depressed mood, irritability, and anxiety" from day 0 to day 90 of the trial. In the MG-LAB279 strain group, the number of days was significantly lower compared to the placebo group. In the comparison between the two groups, a significance level of less than 5% was considered statistically significant. These results indicate that the MG-LAB279 strain has an effect of improving mood.

[0056] Figure 4 shows the results of subjective evaluations regarding fatigue. Figure 4 shows the changes in fatigue VAS test results on day 0, day 42, and day 90 of the study. On day 90, the MG-LAB279 strain group showed a significant improvement in scores compared to the placebo group. In the comparison between the two groups, a significance level of less than 5% was considered statistically significant. These results indicate that the MG-LAB279 strain has an effect of reducing fatigue.

[0057] Figure 5 shows the results of subjective evaluations regarding sleep. Figure 5 shows the changes in the OSA sleep questionnaire results on day 0, day 42, and day 90 of the study. On day 90, the MG-LAB279 strain group showed a significant improvement in scores compared to the placebo group. In the comparison between the two groups, a significance level of less than 5% was considered statistically significant. These results indicate that the MG-LAB279 strain has the effect of reducing morning sleepiness.

[0058] Figure 6 shows the measurement results regarding the skin moisture content of male subjects. Figure 6 shows the changes in the stratum corneum moisture content of the skin on the inner right forearm on day 0, day 42, and day 90 of the study. On day 90, the decrease in moisture content was significantly suppressed in the MG-LAB279 strain group compared to the placebo group. In the comparison between the two groups, a significance level of less than 5% was considered statistically significant. These results indicate that the MG-LAB279 strain has the effect of retaining skin moisture (in other words, suppressing skin dryness).

[0059] [Test Example 2] Oral administration test to alcohol-ingested mice (Test method) BALB / cJ mice were classified into the following three groups (3 mice per group): Negative control group: Group that ingested a standard diet (feed without lactic acid bacteria) Positive control group: Group that ingested a standard diet (feed without lactic acid bacteria) and an ethanol aqueous solution MG-LAB279 strain group: Group that ingested a diet supplemented with MG-LAB279 strain and an ethanol aqueous solution

[0060] As feed, the negative and positive control groups were given a standard diet (MF: manufactured by Oriental Yeast Co., Ltd.) as ad libitum. In the MG-LAB279 strain group, the sterilized powder prepared in Example 1 was mixed with the standard diet at a concentration of 0.5% by mass, and this was given as ad libitum, simulating an intake of 15 mg of MG-LAB279 strain per day. The administration period for MG-LAB279 strain was 24 days, with the start of MG-LAB279 strain administration designated as day 0.

[0061] During the periods from day 7 to day 10, from day 14 to day 17, and from day 21 to day 23, drinking water was not provided, but a 5 vol% ethanol aqueous solution (99.5% ethanol: for HPLC, Fujifilm Wako Pure Chemical Industries, Ltd.) was allowed free access to. During the periods from day 11 to day 13 and from day 18 to day 20, which were designated as liver-free days, drinking water was allowed free access to, but the ethanol aqueous solution was not provided.

[0062] (Evaluation items) Body weight, food intake, and ethanol solution intake were measured to assess the animals' physical condition. In addition, their external appearance was observed on the final day of the study. Serum was collected on the final day of the study to assess liver function, and biochemical tests were performed.

[0063] (Experimental Method) Body weight and food intake were measured twice a week. Food intake was calculated by subtracting the weight of the feeder after food intake from the weight of the feeder immediately after filling with food. In addition, spilled food in the cage was sifted and separated from the bedding and feces, and its weight was measured and subtracted from the food intake as the amount of spilled food. The food intake was divided by the number of animals and the number of days elapsed to obtain the average daily food intake per animal.

[0064] The amount of ethanol solution consumed was measured daily during the period of consumption. The amount consumed was calculated by subtracting the weight of the water bottle after drinking the following day from the weight of the water bottle at the time of setup. The average daily intake of ethanol solution per animal was calculated by dividing the total intake by the number of animals.

[0065] On the final day of the study (24th day from the start of the study), a necropsy was performed under isoflurane inhalation anesthesia, and blood was collected from the posterior vena cava. The collected blood was dispensed into micro-blood collection tubes (Capiject II, containing serum separator and coagulation accelerator, Terumo Corporation). After standing at room temperature for 30 minutes to 2 hours, the serum was obtained by centrifugation at 20°C and 2900G for 10 minutes using a micro-high-speed centrifuge. The obtained serum was analyzed by an animal blood testing service (Oriental Yeast Co., Ltd.).

[0066] (Results) Body weight, food intake, ethanol aqueous solution intake, and the appearance of the mice on the last day of the experiment are shown in Figure 7 (Figures 7A-7D). As shown in Figures 7A and 7B, the positive control group showed a decrease in body weight and food intake from the 14th day of the experiment. This is thought to be due to a deterioration in physical condition caused by ethanol intake. Also, as shown in Figure 7D, the positive control group showed deterioration in coat condition on the last day of the experiment. On the other hand, the MG-LAB279 group did not show a decrease in body weight or food intake, nor deterioration in coat condition. These results indicate that the MG-LAB279 strain has the effect of mitigating chronic alcohol-related disorders.

[0067] The results of serum biochemical tests are shown in Figure 8 (Figures 8A to 8D). AST, ALT, LDH, LDL-C, and HDL-C in the blood are markers indicating the state of the liver. As shown in Figures 8A to 8D, the positive control group showed a significant increase in AST, LDH, and LDL-C levels compared to the negative control group, suggesting that ethanol intake caused liver damage. On the other hand, in the MG-LAB279 group, the AST, LDH, and LDL-C levels were similar to those of the negative control group. These results indicate that the MG-LAB279 strain has the effect of mitigating liver damage caused by continuous alcohol intake.

[0068] [Test Example 3] Oral administration test in adult males (Test formulation) Hard capsules containing 30 mg of dried sterilized powder of MG-LAB279 strain

[0069] (Test Method) Eight adult males aged 20 to 70 years, weighing 50 to 90 kg (average age 47.9 ± 9.0 years, average weight 68.0 ± 7.6 kg), were given one capsule once a day for two weeks, within 30 minutes after breakfast.

[0070] (Results) The average body fat mass of the subjects before capsule intake was 17.5 ± 5.9 kg, while the average body fat mass after two weeks was 16.9 ± 6.1 kg, indicating a significant decrease in body fat mass. Furthermore, a decrease in body fat mass was confirmed in 7 out of 8 subjects.

[0071] [Supplement based on Rule 26, 03.07.2025]

Claims

1. A composition for activating plasmacytoid dendritic cells (pDCs), comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its cellular components as an active ingredient.

2. The composition according to claim 1, wherein the activation includes improving the expression of at least one gene selected from the group consisting of HLA-DR, CD197 (CCR7), CD40, CD83, and CD86.

3. A composition for improving the expression of at least one gene selected from the group consisting of HLA-DR, CD197 (CCR7), CD40, CD83, and CD86 in plasmacytoid dendritic cells (pDCs), comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its cellular components as an active ingredient.

4. A composition for improving the intestinal environment, containing Lactobacillus sakei MG-LAB279 strain (accession number: NITE BP-03645) and / or its bacterial components as active ingredients.

5. A composition for improving abdominal discomfort, comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient.

6. A composition for improving abdominal pain, comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient.

7. A composition for improving appetite, comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient.

8. A composition for improving mood, comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its cellular components as an active ingredient.

9. A composition for reducing fatigue, comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its cellular components as an active ingredient.

10. A composition for reducing drowsiness, comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient.

11. A composition for suppressing skin dryness, comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its cellular components as an active ingredient.

12. A composition for improving liver function, comprising Lactobacillus sakei MG-LAB279 strain (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient.

13. A composition for reducing body fat, comprising Lactobacillus sakei strain MG-LAB279 (accession number: NITE BP-03645) and / or its bacterial components as an active ingredient.

14. Food and beverage comprising the composition described in any one of claims 1 to 13.

15. A pharmaceutical product comprising the composition described in any one of claims 1 to 13.

Images